0.52
+0.0666(+14.82%)
Currency In USD
| Previous Close | 0.45 |
| Open | 0.46 |
| Day High | 0.52 |
| Day Low | 0.44 |
| 52-Week High | 737.5 |
| 52-Week Low | 0.36 |
| Volume | 2.44M |
| Average Volume | 2.49M |
| Market Cap | 1.89M |
| PE | 0 |
| EPS | -6,321.5 |
| Moving Average 50 Days | 0.81 |
| Moving Average 200 Days | 23.66 |
| Change | 0.07 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of June 30, 2025 at a share price of $0.516. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0.03 as of June 30, 2025 at a share price of $0.516.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis
GlobeNewswire Inc.
9 hours ago
The SEISMiC C Study is the third study in the istaroxime cardiogenic shock development program - SEISMiC C is studying more severely ill SCAI Stage C cardiogenic shock patients Windtree has previously reported two positive early cardiogenic shock Pha
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel
GlobeNewswire Inc.
Jun 26, 2025 8:05 PM GMT
Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of 2026 Tech transfer underway with validation batch manu
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of